MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to assess pharmacokinetics, safety, tolerability and brain penetration of MIN-102 after administration of single ascending doses and multiple ascending doses in healthy volunteers. Results are expected by the end of the year.<\/p>\n
X-linked\u00a0Adrenoleukodystrophy\u00a0(X-ALD)\u00a0is rare and chronically debilitating life threatening neurodegenerative disease, caused by mutations on the ABCD1 gene.\u00a0It is characterized by the accumulation of very long chain fatty acids (VLCFA) leading to a neurodegenerative disorder where the most affected tissues are the spinal cord, the brain and the adrenal cortex.\u00a0Its estimated incidence is 1:17,000 newborns worldwide,\u00a0primarily males\u00a0Currently, there are no therapeutic drugs for X-ALD. MIN-102 is the only product in development for potential use across all the main phenotypes.<\/p>\n
\u201cThe dosing of the first subjects in the Phase 1 trial is an important milestone for Minoryx. It brings us a step closer to offering a potentially meaningful therapeutic option for X-ALD,\u201d said Marc Martinell, CEO of Minoryx. \u201cWe eagerly await the clinical readout from this study and plan to initiate clinical trials in X-ALD patients by early 2017.\u201d<\/p>\n
Minoryx is a drug development company specializing in the discovery and development of new drugs for orphan diseases. The company \u2013located at TecnoCampus Matar\u00f3-Maresme, with laboratories\u00a0at Barcelona Science Park (PCB)\u2013\u00a0targets Inborn Errors of Metabolism, a group of rare diseases of genetic origin with a high unmet medical need. The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has raised a total of \u20ac24.4M ($27.6M).<\/p>\n","protected":false},"excerpt":{"rendered":"